期刊文献+

混合血清经量值传递后用于酶活性测定的定标 被引量:1

Calibration of enzymatic activity determination using home-made mixed serum transmitted by quality
下载PDF
导出
摘要 目的探讨混合血清经酶校准品量值传递后,用于标定血清酶活性定量测定的因子数的可行性。方法用Trucal U复合校准血清和经量值传递的混合血清分别定标血清丙氨酸氨基转移酶(ALT),门冬氨酸氨基转移酶(AST)、碱性磷酸酶(ALP)、γ-谷氨酰转肽酶(GGT)、活性测定的因子数以及理论K值计算法,分别测定20份新鲜血清样品中四种酶的活性。结果1、TruCal复合标准血清标定后的测定结果与理论K值计算法测定结果比较,ALP、GGT的相对偏倚分别为-25.21%和15.67%,作回归分析和配对t检验,(t=15.644和3.846,P<0.001)。与经量值传递的混合血清标定后的测定结果比较,ALP、GGT的相对偏倚分别为2.31%和0.98%。2、混合血清标定后,测定高、中、低三个水平的混合血清及TruCal U复合校准血清,CV%、相对偏倚均小于5%,但低值样品的ALT、AST的CV%为9.08和7.68。结论经量值传递的混合血清标定血清酶活性定量测定的因子数,可以提高血清酶测定的因子数,可以提高血清酶活性测定的准确度,使血清酶活性定量测定的结果有可溯源性。 Objective To investigate the feasibility of using home-made mixed serum transmitted by quality to calibrate calibration factor in enzymatic activity determination. Mechods Factors were calibrated in enzymatic activity measurement of ALT,AST,ALP,GGT with TruCal U calibrator serum and home-made mixed serum separately,and then the enzymatic activity of ALT,AST,GGT in twenty fresh serum was determined with K-value calculation. Resuits 1. By comparing the results calibrated by TruCal O calibrator serum with the results calculated with K-value calculation,the relative variability of ALP and GGT was -25. 21% and 15.76 %. Then results of regression analysis and t-test were t= 15. 644 and 3. 846,P〈0. 001. While by comparing the results calibrated by home-made mixed serum with the results calibrated by TruCal U calibrator serum,the relative variability of ALP and GGT was 2.31% and 0. 98%. 2. Both CV% and relative variability were less than 5% in mixed serum of high,media,low grade and TruCal U calibrator serum,but CV% of ALT,AST in low grade was 9. 08 and 7. 68. Conclusion The accuracy and measurement traceability can be improved when home-made mixed serum is used to calibrate enzymatic activity measurement.
作者 张林
出处 《淮海医药》 CAS 2007年第4期290-292,共3页 Journal of Huaihai Medicine
关键词 酶活性测定 酶校准品 溯源性 Calibrator Enzymatic activity determinant Measurement traceability
  • 相关文献

参考文献5

二级参考文献16

  • 1冯仁丰.临床检验质量管理技术基础.上海:科学技术文献出版社,2003,7:22-23
  • 2[1]National Committee for Clinical Laboratory Standards. Evaluation of Matrix Effects; Approved Guideline [S]. NCCLS Document EP-14A.Wayne, PA:NCCLS,2000.
  • 3[2]U.S Department of Health and Human Services. Medicare, Medicaid and CLIA Programs: Regulations implementing the Clinical Improvement Amendment of 1988(CLIA) [S].Final rule. Fed Rigest 1992,57:7002-7186.
  • 4[3]CRM 470, The certification of matrix reference material for immunochemical measurement 14 human serum proteins[S].commission of the european communities, Brussels, 1993.
  • 5European Union. Directive 98/79/EC of the european parliament and of the council of 27 october 1998 on in vitro diagnostic medical devices.Official Journal of the European Communities, 1998, L331 : 1-37.
  • 6International Organization for Standardization. In vitro diagnostic medical devices-measurement of quantities in samples of biological originmetrological traceability of values assigned to calibrators and control materials. ISO/DIS 17511, International Organization for Standardization,Geneva,2000.
  • 7International Organization for standardization. In vitro diagnostic medical devices-measurement of quantities in samples of biological originmetrological traceability of values for catalytic concentration of enzymes assigned to calibrators and control materials. ISO/DIS 18153,International Organization for Standardization, Geneva, 2000.
  • 8International Organization for Standardization. General requirements for the competence of testing and calibration laboratories. ISO/IEC 17025,International organization for standardization, Geneva, 1999.
  • 9International Organization for Standardization. Quality management i0n the medical laboratory. ISO/FDIS 15189, International Organization for Standardization, Geneva, 2000.
  • 10Siekmann L. Traceability of calibration for IVD industry: Process for eredentialing reference materials, reference methods and reference laboratories in europe. In: proceedings of the workshop on measurement traceability for clinical laboratory testing and in vitro diagnostic test systems. National Institute of Standards and Technology, Gaithersburg MD, 2000. 85-101.

共引文献117

同被引文献14

  • 1王喜栋,路曦,宫心鹏,马书臣.标本溶血对生化检验结果的影响[J].河北医药,2004,26(8):663-663. 被引量:23
  • 2Sonntag O. Haemolysis as an interference factor in clinical chemistry [ J ]. Clin Chem Clin Biochem, 1986, 24 (2) : 127 - 139.
  • 3Giuseppe Lippi, Salvagno GL, Montagnana M. Influence of hemolysis on routine clinical chemistry testing[ J]. Clin Chem Lab Med, 2006, 44(3) :311 -316.
  • 4Guder WG. Thrombocytes as an interfering factor in chnical chemistry[J].Clin Chem Clin Biochem, 1990, 28(7) :445.
  • 5Sharma, Aabha; Ayling, Ruth M. Detection of haemolysis and reporting of potassium results in samples from neonates[ J]. Annals of clinical biochemistry, 2009, 46 ( Pt3 ) :222 - 225.
  • 6Grafmeyer D, Bondon M, Manchon M. The influence of bilirubin, haemolysis and turbidity on 20 analytical tests performed on automatic analysers. Results of an interlaboratory study[J].Eur. Cliu Chem Clin Bioehem,1995, 33(1) :31 -52.
  • 7Vermeer HJ, Steen G, Naus AJ. Correction of patient results for Beckman Coulter LX - 20 assays affected by interference due to hemoglobin, bilirubin or lipids: a practical approach[J]. Clin Chem Lab Med, 2007,45(1) :114- 119.
  • 8Guder WG. Hemolysis as an influence and Interference factor in clinical chemistry [ J ]. Clin C hem Clin Biochem, 1986,24 (2) :125 - 126.
  • 9Gobert De Paepe E, Munteanu G, Schischmanoff PO. Haemolysis and turbidity influence on three analysis methods of quantitative determination of total and conjugated bilirubin on AI)VIA 1650 [ J]. Ann Biol Clin (Paris), 2008,66(2) :175 - 182.
  • 10Randall AG, Garcia - Webb P, Beilby JP. Interference by haemolysis, icterus and lipaemia in assays on the Beckman Synchron CX5 and methods for correction [ J ]. Ann Clin Biochem, 1990, 27 ( Pt4 ) : 345 - 352.

引证文献1

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部